Determination of binding characteristics as a measure for effective albumin using different methods.
暂无分享,去创建一个
G. Reibnegger | K. Schnurr | V. Fengler | K. Oettl | S. Schwaminger | Margret Paar | K. Waterstradt | Rudolf E Stauber
[1] R. Guzzi,et al. Interactive multiple binding of oleic acid, warfarin and ibuprofen with human serum albumin revealed by thermal and fluorescence studies , 2022, European Biophysics Journal.
[2] Daniel J. Rosenberg,et al. Albumin in patients with liver disease shows an altered conformation , 2021, Communications biology.
[3] M. Bartolini,et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications , 2021, Hepatology.
[4] Huan‐Xiang Zhou,et al. Fatty Acids Compete with Aβ in Binding to Serum Albumin by Quenching Its Conformational Flexibility. , 2019, Biophysical journal.
[5] A. Gasbarrini,et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial , 2018, The Lancet.
[6] J. Stange,et al. Targeting Albumin Binding Function as a Therapy Goal in Liver Failure: Development of a Novel Adsorbent for Albumin Dialysis , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[7] E. Bourdon,et al. Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide , 2018, The Journal of Biological Chemistry.
[8] J. Hartmann,et al. Removal of stabilizers from human serum albumin by adsorbents and dialysis used in blood purification , 2018, PloS one.
[9] M. Otagiri,et al. Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations. , 2015, Journal of pharmaceutical sciences.
[10] M. Naldi,et al. Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis , 2014, Hepatology.
[11] D. Giustarini,et al. Cigarette smoke induces alterations in the drug-binding properties of human serum albumin. , 2014, Blood cells, molecules & diseases.
[12] R. Stauber,et al. Human Nonmercaptalbumin‐2: A Novel Prognostic Marker in Chronic Liver Failure , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[13] M. Otagiri,et al. Cys34-Cysteinylated Human Serum Albumin Is a Sensitive Plasma Marker in Oxidative Stress-Related Chronic Diseases , 2014, PloS one.
[14] R. Jalan,et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications , 2013, Hepatology.
[15] R. Stauber,et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. , 2013, Journal of hepatology.
[16] D. S. Hage,et al. Review: Glycation of human serum albumin. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[17] E. Bourdon,et al. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. , 2012, Biochimie.
[18] C. Shearman,et al. Effects of nonenzymatic glycation and fatty acids on functional properties of human albumin. , 2011, Metabolism: clinical and experimental.
[19] E. Reisinger,et al. Industrial stabilizers caprylate and N‐acetyltryptophanate reduce the efficacy of albumin in liver patients , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] S. Curry,et al. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin , 2011, Journal of structural biology.
[21] D. S. Hage,et al. The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan. , 2010, Journal of pharmaceutical and biomedical analysis.
[22] K. Schnurr,et al. Fatty acid binding sites of human and bovine albumins: differences observed by spin probe ESR. , 2009, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[23] Roger Williams,et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality , 2009, Hepatology.
[24] M. Davies,et al. What are the plasma targets of the oxidant hypochlorous acid? A kinetic modeling approach. , 2009, Chemical research in toxicology.
[25] S. Era,et al. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin. , 2009, International journal of peptide and protein research.
[26] R. Stauber,et al. Oxidative damage of albumin in advanced liver disease. , 2008, Biochimica et biophysica acta.
[27] H. Kaneto,et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. , 2008, Endocrine journal.
[28] P. Taboada,et al. Effect of solvation on the structure conformation of human serum albumin in aqueous–alcohol mixed solvents , 2007 .
[29] R. Stauber,et al. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties , 2007, British journal of pharmacology.
[30] S. Kazmierczak,et al. Electron spin resonance spectroscopy of serum albumin: a novel new test for cancer diagnosis and monitoring. , 2006, Clinical chemistry.
[31] T. Amisaki,et al. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids , 2006, Proteins.
[32] S. Curry,et al. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. , 2006, Journal of molecular biology.
[33] P. Ascenzi,et al. Allosteric modulation of drug binding to human serum albumin. , 2006, Mini reviews in medicinal chemistry.
[34] S. Curry,et al. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[35] Toru Maruyama,et al. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. , 2003, Biochimica et biophysica acta.
[36] G. Hersmann,et al. Albumin transport analysis of different collected and processed plasma products by electron spin resonance spectroscopy. , 2002, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[37] S. Era,et al. Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[38] M. Otagiri,et al. Effect of Oxidative Stress on the Structure and Function of Human Serum Albumin , 2001, Pharmaceutical Research.
[39] S. Mitzner,et al. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. , 2001, Zeitschrift fur Gastroenterologie.
[40] P. Brick,et al. Fatty acid binding to human serum albumin: new insights from crystallographic studies. , 1999, Biochimica et biophysica acta.
[41] P. Sadler,et al. A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy. , 1994, European journal of biochemistry.
[42] R G Reed,et al. The albumin receptor effect may be due to a surface-induced conformational change in albumin. , 1989, The Journal of biological chemistry.
[43] G. H. Faber,et al. Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin. , 1985, Journal of pharmaceutical sciences.
[44] G. Marsche,et al. Redox state of human serum albumin in terms of cysteine-34 in health and disease. , 2010, Methods in enzymology.
[45] M. Otagiri,et al. Kinetic studies of covalent binding between N-acetyl-L-cysteine and human serum albumin through a mixed-disulfide using an N-methylpyridinium polymer-based column. , 2004, Drug metabolism and pharmacokinetics.